NEW YORK, Nov. 3, 2026 /CNW/ -- Equity Insider News Commentary - Tuesday's session reversed the pattern of the day before. On Monday, the Dow Jones Industrial Average was the only one of the four major U.S. stock
Cecile Guegan to lead Pfizer’s financial strategy as Chief Financial Officer with over 25 years of pharmaceutical finance experience
Pfizer Inc. (NYSE:PFE) today announced that its Board of Directors has unanimously
In the Phase 3 MagnetisMM-32 trial, ELREXFIO demonstrated a clinically meaningful and statistically significant benefit for patients whose disease progressed after anti-CD38 therapy and lenalidomide, with median PFS
TALZENNA plus XTANDI is now approved for HRR gene-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer, offering a potential new standard of care earlier in the course of
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Cancer treatment is moving into a new phase, and immuno-oncology is right at the center of it. Instead of relying only on drugs that attack tumors directly, researchers are
Investigational vaccine shows strong immune responses in infants equivalent to PREVNAR 20® on shared serotypes and for five new serotypes, potentially offering the broadest protection against invasive pneumococcal
DENVER, Oct. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — Healthcare stocks are presenting investors with a mix of pharmaceutical growth stories and catalysts. Pfizer (NYSE:PFE) is drawing renewed attention to
Data from 57 abstracts will highlight Pfizer’s scientific progress targeting infectious diseases, including pneumococcal disease and RSV
Pfizer Inc. (NYSE:PFE) will present data from more than 50 company-sponsored,
TUKYSA in combination with trastuzumab and pertuzumab showed more than 50% improvement in median progression-free survival, supporting approval as a chemotherapy-free maintenance option
Pfizer Inc. (NYSE:PFE) today
– PADCEV™ (enfortumab vedotin) plus pembrolizumab data highlight durable survival benefit in advanced bladder cancer –– VYLOY™ (zolbetuximab) research reinforces the role of CLDN18.2 in shaping gastric cancer treatment
Pfizer Board of Directors approves fourth-quarter 2026 cash dividend of $0.43 per share
Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2026 dividend on the
LITFULO significantly improved facial and total body repigmentation at Week 52 compared to placebo, with continuous improvement starting at Week 24, supporting planned regulatory filings for a potential new oral
Study met primary endpoint, showing a statistically significant increase in the percentage of participants achieving EASI-75 versus placebo at Week 16, for the potentially first-in-class trispecific antibody
Pfizer
Data across 45 abstracts will highlight new evidence for established medicines, including PADCEV and TALZENNA, and promising late-stage pipeline candidates such as atirmociclib and tivunatamig (PF’4404)
Pfizer Inc.
